AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
- New single-dose vaccine offers broad protection against three major poultry diseases, improving bird health and easing the operational burden on farms.
- Strengthens poultry portfolio in India with two launches in the past one year.
Boehringer Ingelheim, a global leader in animal health, has announced the launch of its latest poultry vaccine in India—a single-dose, next-generation solution that provides protection against Bursal, Newcastle, and Marek’s disease.
This innovative vaccine is designed to address the practical challenges faced by poultry farmers in India, offering early, reliable, and long-lasting immunity with just one administration at the hatchery.
With poultry playing a vital role in India’s food supply and rural economy, disease outbreaks remain a serious threat to both productivity and profitability. This new vaccine offers a streamlined approach to disease prevention by reducing the need for multiple field vaccinations, lowering labor requirements, and minimizing bird handling stress—all while maintaining strong disease control across production systems.
Dr. Vinod Gopal, Country Head-Animal Health, Boehringer Ingelheim India, emphasized the company’s focus on local needs, “We understand the pressure Indian poultry farmers face—from disease control to operational efficiency. This vaccine reflects our commitment to bringing science-led, farmer-focused innovations to the market. By combining protection into a single dose, we are helping farmers enhance productivity, improve bird welfare, and build more resilient operations.”
Dr. K. S. Prajapati, Former HOD, Dept. of Vet. Pathology, College of Vet. Science, AAU, Anand commented on the significance of this advancement, “Farmers need solutions that are both effective and practical. The evolving disease landscape demands smarter protection strategies. A vaccine that offers early, combined immunity against three major diseases is a valuable tool that helps farmers secure their flocks and reduce reliance on antibiotics.”
The vaccine is suitable for broilers, layers, and breeders, and can be administered either in ovo or via subcutaneous injection at the hatchery.
Boehringer Ingelheim Animal Health
Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society.
Learn more at www.boehringer-ingelheim.com/animal-health.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow.
Established in 2003, Boehringer Ingelheim India manages operations in India and neighbouring markets, offering innovative products in Human Pharma and Animal Health, with key therapy areas including diabetes, cardiovascular, and respiratory conditions. Learn more at https://www.boehringer-ingelheim.com/in.